Efficacy and safety of a single dose of nirsevimab against respiratory syncytial virus infection in infants: a meta-analysis and time-to-event analysis Authors: Mohamed Saad Sayed, Mena Ayman Elgendy, Nada Gamil, Hossam Hassan Abdullah, Alaa Alhwary, Rahma Abdulfattah Ibrahim, Sama Hesham Samir, Nada S. Jibril, Hebatullah Abdulazeem, Mohammed Alsabri Published: 2025 ABSTRACT Respiratory syncytial virus (RSV) is one of the causes of lower respiratory tract infections (LRTIs) and related hospitalizations in neonates and infants. Clinical trials have shown that a single dose of nirsevimab can prevent this infection and its related complications. We systematically searched PubMed, Embase, Web of Science (WOS), Scopus, and Cochrane Central on 25 November 2024 and updated on 18 April 2025, without automated filters or language restrictions. Studies reported the outcomes after nirsevimab in infants were retrieved. A random effects model was applied for analysis. A total of 425,362 infants were pooled from 26 studies (6 randomized controlled trials and 20 observational cohorts studies). The immunization with nirsevimab reduced the incidence of RSV-LRTIs by 63% (risk ratio [RR]: 0.37; 95% CI [0.29; 0.47], p-value < 0.001, I2 = 91.77%), hospitalization by 73% (RR: 0.27; 95% CI [0.20; 0.37], p-value < 0.001, I2 = 97.46%). Nirsevimab also reduced the incidence of all-cause LRTIs and hospitalization, bronchiolitis, ICU admission, emergency unit visits, and all-cause mortality. The high heterogeneity was raised from pooling the real-world data across different clinical settings such as different geographical locations. There was no statistical significance regarding safety outcomes; serious, GIT adverse events, adverse events of special interest, and adverse events > grade 3 between the two groups. The time to event analysis showed that nirsevimab significantly reduced the RSV-LRTIs (Hazard Ratio (HR): 0.25; 95% CI [0.16; 0.37]) and hospitalization (HR: 0.14; 95% CI [0.08; 0.25]). The immunization with a single dose of nirsevimab significantly reduced the RSV-LRTIs and hospitalization in infants who were at risk for RSV infection without any identified safety concerns. The long-term safety concerns are still unclear across the current studies.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13052-025-02184-4. Introduction Respiratory syncytial virus (RSV) is classified as the major cause of lower respiratory tract infections (LRTIs) and lower respiratory tract infection-related hospitalization among young infants [1]. The latest observational study regarding the prevalence of RSV infection among term infants in the US reported that more than half of the cohort acquired RSV infection during their first year of life [2]. The risk of RSV-related LRTIs is 15.9% with 2.8% requiring hospitalization due to LRTIs [2]. And, the preterm infants were exposed to severe infections, other than term infants [2]. Therefore, there is a growing need for preventive strategies to address serious RSV infections. Hence, the standard care for RSV infection is supportive treatment, and there is no curative treatment. The RSV maternal vaccine, the Respiratory Syncytial Virus preF vaccine (ABRYSVO), has been recently approved by the United States Food and Drug Administration (FDA) for pregnant women as an active immunization method against neonatal RSV infection [3]. However, it was associated with a higher risk of preterm labor [4]. The Palivizumab, a short-term monoclonal antibody against RSV, is used as a passive immunization agent in high-risk infants to prevent serious RSV infections [5]. It was associated with lower hospitalization rates, but with high cost and short duration of action. That is why the medical community needs a new prophylactic agent that shows advantages over palivizumab [5]. Nirsevimab is a recombinant long-acting monoclonal antibody to the prefusion conformation of RSV F protein [6]. It also contains a triple amino acid substitution in the Fc domain that extends its half-life, allowing for a single dose to cover a typical RSV season in regions with temperate climates [7]. The European Medicines Agency (EMA) suggests that it should be used as an intramuscular injection for infants during their first RSV season, and for infants born during the RSV season [5]. Others born outside the RSV season should receive it before the season begins [5]. Due to its recent introduction, there is no clear evidence about the safety and efficacy of nirsevimab in preventing severe RSV infection in infants and neonates. The past meta-analyses that relied on the randomized clinical trials, which were published from 2023 to 2024, evaluated the higher efficacy of nirsevimab to reduce the RSV infections within a good safety profile [8–11]. Also, a recent meta-analysis, which was published in 2025, pooled the overall observational studies, both cohort and case-control studies, and revealed a higher efficacy profile of nirsevimab [12]. However, real-world evidence from recent randomized controlled trials (RCTs) and observational cohort studies has emerged. Therefore, we aimed to pool these recent studies to obtain clear evidence for the use of nirsevimab in immunization protocols. This analysis will evaluate both efficacy and safety outcomes. In this systematic review and meta-analysis, we aim to fill the gap and provide clear evidence regarding the safety and efficacy of a single dose of nirsevimab for the prevention of RSV serious infections in infants by reviewing the available RCTs and cohort studies. Through using the individualized patient data (IPD) analysis using Kaplan-Meier reconstruction, the cumulative hazard of LRTIs and hospitalization related to RSV will be evaluated. Methods We conducted and designed the present systematic review and meta-analysis by following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Statement [13]. In addition to the PRISMA Statement, the Cochrane Handbook for Systematic Reviews of Interventions was used to conduct this review [14]. The protocol for this meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO) under the registration number (Prospero ID: CRD42025634933). The ethical approval was waived because the authors used the data from already published articles. Literature search This systematic review aimed to answer our research question: “Is a single dose of Nirsevimab safe and effective to reduce RSV infections’ LRTIs and Hospitalization?”. A pilot study was conducted to inform the development of an inclusive search strategy for the literature. The search strategy was implemented across multiple databases, including PubMed via Medline, Embase via Ovid, Web of Science via Clarivate Analytics, CENTRAL via Cochrane Library, and Scopus via Elsevier, without automated filters. The search was conducted on 25 November 2024 without any language restrictions. We have also updated the search on 18 April 2025. A combination of various terms related to Nirsevimab and Respiratory Syncytial Virus (e.g., Nirsevimab, Respiratory Syncytial Virus Infection, RSV Infection, Respiratory Syncytial Virus) was employed in the search strategy. The detailed search strategy, including all keywords, entry terms, and combinations applied in each database, is found in (Supplementary Table 1). Two independent authors (M.S.S. and R.A.I.) manually searched the first 300 hits in Google Scholar to search for any dropped articles. And the citation and reference of the included studies were tracked to search the any dropped studies. Eligibility criteria We considered RCTs and observational cohort studies, which assessed the safety and efficacy outcomes of nirsevimab in healthy infants below two years who are at risk of RSV infections. The PICOS format was as follows: Population [P]: healthy infants without current respiratory syncytial virus infections.Intervention [I]: single dose of nirsevimab.Comparison [C]: a placebo as a comparison or observed the infants undergoing standard care.Outcomes [O]: efficacy (RSV infection or related hospitalization) and safety outcomes.Study design [S]: RCTs and observational cohort studies, either prospective or retrospective. Population [P]: healthy infants without current respiratory syncytial virus infections. Population [P]: healthy infants without current respiratory syncytial virus infections. Intervention [I]: single dose of nirsevimab. Intervention [I]: single dose of nirsevimab. Comparison [C]: a placebo as a comparison or observed the infants undergoing standard care. Comparison [C]: a placebo as a comparison or observed the infants undergoing standard care. Outcomes [O]: efficacy (RSV infection or related hospitalization) and safety outcomes. Outcomes [O]: efficacy (RSV infection or related hospitalization) and safety outcomes. Study design [S]: RCTs and observational cohort studies, either prospective or retrospective. Study design [S]: RCTs and observational cohort studies, either prospective or retrospective. Case-control studies were not eligible for consideration in our analysis. This decision was made because the baseline of these studies included infants infected with RSV. Exclusion criteria include reviews, editorials, guidelines, letters, case reports, case series, and conference abstracts. Selection process After the database search, duplicates were automatically removed using EndNote 21. Subsequently, the remaining articles underwent assessment based on predefined inclusion and exclusion criteria through title and abstract screening by four independent investigators (H.H., R.A.I., S.N., M.A.E.) using Rayyan AI [9]. Any discrepancies were solved through discussion and consensus with the support of another investigator (M.S.S.). The same four investigators reviewed eligible full texts to confirm their inclusion or exclusion. Any conflicts in this stage were also resolved by discussion with another investigator (M.S.S.). Data extraction Specific spreadsheets were formulated by two authors to extract the data. Three sheets were used: summary, baseline, and outcomes sheet. For the summary sheet, we extracted the study ID, study design, country, timeframe of the study, sample size, sample definition, details of intervention or observed group, details of placebo or control group, inclusion criteria, outcomes, and conclusion. For the baseline sheet, we considered sample size in each group, age (months), gestational age (weeks), sex, and weight. The outcomes sheet focused on the primary outcomes: medically attended LRTIs related to RSV (defined by both physical examination and documentation of clinical severity), hospitalization due to RSV, and ICU admission. The secondary outcomes were bronchiolitis occurrence, emergency unit visits, need for mechanical ventilation (mixed types, invasive and non-invasive), all-cause mortality, and safety outcomes (adverse events of special interest, adverse events > grade 3, serious adverse events, GIT adverse events, and infections and infestations). Conflicts were resolved by a discussion within the team of data extraction. Quality assessment and certainty of evidence Two authors (M.A.E. and N.A.H.) independently assessed the quality of the studies using the Cochrane Risk of Bias tool (ROB2) for RCTs and the Newcastle–Ottawa Scale (NOS) designed for cohort studies. ROB2 tool focuses on five domains: randomization process (selection bias), deviation from intended interventions (performance bias), outcome measurement (detection bias), missing outcome data (attrition bias), selection of reported results (reporting bias), and other potential sources of bias [15]. The authors’ decisions were classified as “low risk of bias”, “high risk of bias,” or “some concerns”. NOS scale [16] is a validated tool for evaluating the methodological quality of observational studies, focusing on three domains: selection of study groups (with a maximum of four points), comparability of groups (with a maximum of two points), ascertainment of exposure, and outcomes (with a maximum of three points). Each study received total quality assessment scores ranging from 0 to 9 points, with a score of ≤ 3, 4–6, and ≥ 7 indicating low, moderate, and high quality, respectively [17]. This classification was based on previous publications, as no specific cutoff is recommended. Any conflicts were resolved by discussion with a third reviewer (M.S.S.). The GRADE criteria [18] served as the basis for evaluating the quality of the evidence. In summary, the quality of the evidence from observational studies was initially low and was further rated lower if any of the following factors were present: publication bias, indirectness, imprecision (wide 95% CIs crossing the unity or failure to reach the optimal information size), inconsistency (high heterogeneity in the estimates), and risk of bias in the literature [18]. The GRADE assessment was conducted using GRADEpro GDT (GRADEpro Guideline Development Tool, McMaster University and Evidence Prime, 2024). Data synthesis and analysis The frequencies and total number of events were collected to pool the effects of the included studies. Dichotomous outcomes were analyzed using Risk Ratio (RR) with a corresponding 95% confidence interval (95% CI) by the random-effects model (Der Simonian-Laird). If p-value < 0.05, we considered the outcome to be significant. We used random effects models to handle the differences between studies and address the potential heterogeneity. We used STATA Corp MP17 to analyze the data. As a result of the different study designs of the included studies, we planned to perform subgroup analysis based on the study design. Statistical heterogeneity among studies was assessed by the chi-square test (Cochran’s Q test). Then, the I2 value was calculated using chi-square statistics. A significant heterogeneity was considered when the p-value of the chi-square of less than 0.1. An I2 value ≥ 50% revealed a high heterogeneity. A sensitivity analysis using a leave-one-out model was performed to resolve any significant heterogeneity. Moreover, for every outcome in the meta-analysis, we ran sensitivity analyses in multiple scenarios, excluding one study in each scenario to ensure the overall effect size was not dependent on any single study. Funnel plots were used to explore the publication bias across studies by presenting the relationship between effect size and standard error. Egger’s regression test was used to assess evidence of publication bias. Time-to-event analysis We conducted the individual patient data (IPD) analysis depending on the curve technique [19], which uses the published Kaplan–Meier (KM) graphs from the included RCTs to reconstruct the IPD. We go through two phases. To obtain the raw data coordinates in the form of time and probability from the published KM plots, we first used the online plot digitizer software [https://plotdigitizer.com/]. The IPD data regarding the numbers at risk at specific time points, the corresponding total number of patients, and the total number of incidents [19] were then obtained using the R package IPD from KM (Version 0.1.10), utilizing the raw data coordinates from the digitized KM plots. The final study data set for the entire reconstructed study in the particular outcome (LRTIs and Hospitalizations due to RSV infections) was created by combining the reconstructed IPD for the same outcome once each study reconstruction was complete. Next, we used the following R packages: survival (Version 3.2–13), survminer (Version 0.4.9), and coxph (Version 4.0.2) to fit the Cox proportional hazard models and Kaplan–Meier analyses based on the reconstructed IPD. The reconstructed IPD data set’s hazard ratios (HRs) and associated 95% CI were obtained using the Cox frailty model [20]. We checked the reconstructed Kaplan–Meier curves for resemblance with the original version to make sure our reconstructed IPD dataset produced from the KM curves was accurate enough to replicate the original KM curves. In contrast to the first published curves, all reconstructed curves stayed inside the 99% CI as a result of the preceding stage. The similarity was also assessed using the mean and maximum absolute error as well as the root mean square error. As achieved in our analyses, the values of root mean square ≤ 0.05, mean absolute error ≤ 0.02, and maximum absolute error ≤ 0.05 indicate that the extracted data points are sufficiently well captured for subsequent analyses. During the reconstruction stage, we calculated the median survival or progression time if the probability was cut in half. To quantify the survival or progression probability, the restricted mean survival time (RMST) was calculated, and the difference between the two study arms (Nirsevimab and placebo) was compared [21]. All statistical analyses of IPD were done by using R Statistical Software version 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria). Results Study selection Five databases, Embase, PubMed, Cochrane CENTRAL, Scopus, and WOS, were systematically searched. After records were obtained from databases, the duplicates were removed by EndNote 21, and the remaining records entered screening phases: Title and abstract, then full text. A total of 22 studies [22–43] were eligible to be included after full-text screening. After the manual search and Citation and reference searching, 30 articles were screened, from which four other studies [8–11] were included in our review. A total of 26 studies [8–11, 20–41] were the basis of the systematic review and meta-analysis (Fig. 1). Fig. 1PRISMA flowchart for study selection process through the databases PRISMA flowchart for study selection process through the databases Study characteristics Out of the 26 included studies, five were RCTs [26, 30, 31, 33, 34], one post-hoc study [43], and 20 studies [8–11, 22–25, 27–29, 32, 35–41, 44] were observational cohort studies, either prospective or retrospective. The total included population was 425,362 infants pooled from all included studies. A total of 24 of 26 studies included healthy infants. All five RCTs were multicentric and conducted across multiple countries, were counted 46 countries, most of which are: the USA, Germany, France, Italy, and Spain. Thirteen studies were conducted in Spain [11, 22–25, 28, 32, 35, 36, 39, 41, 42], four in France [8, 11, 37, 38], two in the USA [10, 34], and one in Italy [29]. Table 1 shows the summary of included studies. Table 1Study characteristics of the included studiesStudy IDStudy DesignTimeframeCountrySettingCentersSample size, nThe sample wasAgeDiagnosis toolPrimary outcomesAres-Gómez et al. (2024)Population-based longitudinalSeptember 2023 to December 2023,SpainInpatient careMultiple10,259Healthy infants≤ 24 monthsPCR or RATRSV-H, RSV-LRTIs, and ICU-admissionBuey et al. (2024)Population-based longitudinalOctober 2023 to February 2024SpainInpatient careMultiple37,067Healthy infants< 12 monthsPCR or RATRSV-H and ICU-admissionPerramon-Malavez et al. (2024)Population-based retrospectiveSeptember 2014 to January 2024SpainOutpatient careMultiple15,341Healthy infants≤ 24 monthsRATAll cause bronchiolitis and RSV infections.Mallah et al. (2024)Population-based longitudinal cohortSeptember 2023 to April 2024SpainInpatient careMulticenter14,476Healthy infants< 12 monthsPCR or RATRSV-related LRTI hospitalizationLevy et al. (2024)Prospective multicentric surveillance studySeptember 2017 to January 2024FranceOutpatient careMulticenter2,502Healthy infants≤ 24 monthsRATbronchiolitisRSV-positive bronchiolitis rateEstrella-Porter et al. (2024)Observational retrospective studyOctober 1, 2023, to January 9, 2024SpainInpatient careMultiple27,362Healthy infants< 6 monthsNRRSV infection incidence and hospitalization due to RSVErnest et al. (2024)Observational, retrospective comparisonOctober 2023 to December 2023LuxembourgInpatient careSingle center630Healthy infants< 6 monthsRATRSV hospitalisation ratesVazquez-Lopez et al. (2025)Observational retrospective cohort studyDecember 2022 to December 2023SpainInpatient careMulticenterNRNR≤ 24 monthsPCRBronchiolitisPerramon-Malavez et al. (2025)Retrospective cohort studyOctober 1, 2023, to January 31, 2024SpainOutpatient careSingle center15,341Healthy infants≤ 35 monthsRATRSV-LRTIOcana de Sentuary et al. (2024)Prospective longitudinal cohort studySeptember 18, 2023, to January 23, 2024FranceSingle centerSingle center477Healthy infants< 12 monthsClinical observationAcceptance rate of nirsevimab administrationMoreno-Pérez et al. (2025)Retrospective longitudinal observational cohort studyOctober 2023 to February 2024SpainInpatient careMulticenter222Infants with bronchiolitis< 6 monthsPCRRespiratory supportMa et al. (2024)Population-based cohort study using real-time EMR databaseOctober 1, 2023, to March 31, 2024Primarily USA (some global centers)Outpatient careMulticenter192,677Healthy infants< 12 monthsPCR or RATRSV infectionJabagi et al. (2025)observational cohort studySeptember 2023 to January 2024FranceOutpatient careMulticenter82,474Healthy infants<12 monthsPCRHospitalization for RSV-LRTIGriffin et al. (2020)RCTNovember 2016 to December 2017Multinational (23 countries)Outpatient and inpatient settingsMulticenter1453Healthy infants< 12 monthsRT-PCRRSV-LRTIsDagan et al. (2024)RCT*July2019 and October 2021Multinational (31 countries)Outpatient and inpatient settingsMulticenter3012Healthy infants< 12 monthsRT-PCRRSV-LRTIComa et al. (2024)Retrospective Cohort1 October 2023 to 31 January 2024SpainOutpatient careand inpatient careMulticenter26,525Healthy infants< 12 monthsRATRSV-HospitalizationArbetter et al. (2024)Multicenter RCTJuly 2019 to October 2021MultinationalOutpatient careand inpatient careMulticenter3012Healthy infants≤ 24 monthsPCRRSV-LRTIsAlexis Marouk et al. (2025)Retrospective CohortOctober 2, 2023, to December 31, 2023Franceinpatient careMulticenter739Infants with respiratory compromise< 12 monthsPCRRSV-HospitalizationRuiz et al. (2024)Retrospective CohortOctober 2022 to March 2023.SpainOutpatientMulticenter646Infants with respiratory compromise< 12 monthsPCRRSV-HospitalizationHammitt et al. (2022)Multicenter RCTJuly 2019 to March 2020MulticentersOutpatient careand inpatient careMulticenter1,490Healthy infants≤ 24 monthsPCR and RATRSV-LRTIsGutiérrez et al. (2024)Retrospective CohortWeek 40 to week 52 of 2022 and 2023.SpainOutpatientSingle center765Infants with respiratory compromise< 12 monthsPCREmergency visitsEzpeleta et al. (2024)Prospective cohortOctober 2023 to January 2024SpainInpatientMulticenter1,177Healthy infants< 24 monthsPCRRSV-HospitalizationDrysdale et al. (2023)Multicenter RCTAugust 2022 to February 2023MultinationalOutpatient careand inpatient careMulticenter8,058Healthy infants< 12 monthsPCRRSV-LRTIs and HospitalizationDomachowske et al. (2017)Multicenter RCTNRMultinationalOutpatient careand inpatient careMulticenter89Healthy infants< 12 monthsPCRSafety profileConsolati et al. (2024)Prospective cohortMay 2023 to February 2024ItalyOutpatient careand inpatient careSingle center556Healthy infants< 12 monthsNRRSV-bronchiolitisAlejandre et al. (2024)Prospective cohortSeptember 2010 and February 2024SpainInpatient careSingle center1531Healthy infants< 12 monthsPCRICU admissionRSV: respiratory syncytial virus. ICU-admission: intensive care unit admission. RSV-LRTIs: respiratory syncytial virus-related lower respiratory tract infections. PCR: polymerase chain reaction. RAT: rapid antigen test. NR: not reported*It was a substudy from MELODY study (Hammit et al., 2020) Table 1Study characteristics of the included studiesStudy IDStudy DesignTimeframeCountrySettingCentersSample size, nThe sample wasAgeDiagnosis toolPrimary outcomesAres-Gómez et al. (2024)Population-based longitudinalSeptember 2023 to December 2023,SpainInpatient careMultiple10,259Healthy infants≤ 24 monthsPCR or RATRSV-H, RSV-LRTIs, and ICU-admissionBuey et al. (2024)Population-based longitudinalOctober 2023 to February 2024SpainInpatient careMultiple37,067Healthy infants< 12 monthsPCR or RATRSV-H and ICU-admissionPerramon-Malavez et al. (2024)Population-based retrospectiveSeptember 2014 to January 2024SpainOutpatient careMultiple15,341Healthy infants≤ 24 monthsRATAll cause bronchiolitis and RSV infections.Mallah et al. (2024)Population-based longitudinal cohortSeptember 2023 to April 2024SpainInpatient careMulticenter14,476Healthy infants< 12 monthsPCR or RATRSV-related LRTI hospitalizationLevy et al. (2024)Prospective multicentric surveillance studySeptember 2017 to January 2024FranceOutpatient careMulticenter2,502Healthy infants≤ 24 monthsRATbronchiolitisRSV-positive bronchiolitis rateEstrella-Porter et al. (2024)Observational retrospective studyOctober 1, 2023, to January 9, 2024SpainInpatient careMultiple27,362Healthy infants< 6 monthsNRRSV infection incidence and hospitalization due to RSVErnest et al. (2024)Observational, retrospective comparisonOctober 2023 to December 2023LuxembourgInpatient careSingle center630Healthy infants< 6 monthsRATRSV hospitalisation ratesVazquez-Lopez et al. (2025)Observational retrospective cohort studyDecember 2022 to December 2023SpainInpatient careMulticenterNRNR≤ 24 monthsPCRBronchiolitisPerramon-Malavez et al. (2025)Retrospective cohort studyOctober 1, 2023, to January 31, 2024SpainOutpatient careSingle center15,341Healthy infants≤ 35 monthsRATRSV-LRTIOcana de Sentuary et al. (2024)Prospective longitudinal cohort studySeptember 18, 2023, to January 23, 2024FranceSingle centerSingle center477Healthy infants< 12 monthsClinical observationAcceptance rate of nirsevimab administrationMoreno-Pérez et al. (2025)Retrospective longitudinal observational cohort studyOctober 2023 to February 2024SpainInpatient careMulticenter222Infants with bronchiolitis< 6 monthsPCRRespiratory supportMa et al. (2024)Population-based cohort study using real-time EMR databaseOctober 1, 2023, to March 31, 2024Primarily USA (some global centers)Outpatient careMulticenter192,677Healthy infants< 12 monthsPCR or RATRSV infectionJabagi et al. (2025)observational cohort studySeptember 2023 to January 2024FranceOutpatient careMulticenter82,474Healthy infants<12 monthsPCRHospitalization for RSV-LRTIGriffin et al. (2020)RCTNovember 2016 to December 2017Multinational (23 countries)Outpatient and inpatient settingsMulticenter1453Healthy infants< 12 monthsRT-PCRRSV-LRTIsDagan et al. (2024)RCT*July2019 and October 2021Multinational (31 countries)Outpatient and inpatient settingsMulticenter3012Healthy infants< 12 monthsRT-PCRRSV-LRTIComa et al. (2024)Retrospective Cohort1 October 2023 to 31 January 2024SpainOutpatient careand inpatient careMulticenter26,525Healthy infants< 12 monthsRATRSV-HospitalizationArbetter et al. (2024)Multicenter RCTJuly 2019 to October 2021MultinationalOutpatient careand inpatient careMulticenter3012Healthy infants≤ 24 monthsPCRRSV-LRTIsAlexis Marouk et al. (2025)Retrospective CohortOctober 2, 2023, to December 31, 2023Franceinpatient careMulticenter739Infants with respiratory compromise< 12 monthsPCRRSV-HospitalizationRuiz et al. (2024)Retrospective CohortOctober 2022 to March 2023.SpainOutpatientMulticenter646Infants with respiratory compromise< 12 monthsPCRRSV-HospitalizationHammitt et al. (2022)Multicenter RCTJuly 2019 to March 2020MulticentersOutpatient careand inpatient careMulticenter1,490Healthy infants≤ 24 monthsPCR and RATRSV-LRTIsGutiérrez et al. (2024)Retrospective CohortWeek 40 to week 52 of 2022 and 2023.SpainOutpatientSingle center765Infants with respiratory compromise< 12 monthsPCREmergency visitsEzpeleta et al. (2024)Prospective cohortOctober 2023 to January 2024SpainInpatientMulticenter1,177Healthy infants< 24 monthsPCRRSV-HospitalizationDrysdale et al. (2023)Multicenter RCTAugust 2022 to February 2023MultinationalOutpatient careand inpatient careMulticenter8,058Healthy infants< 12 monthsPCRRSV-LRTIs and HospitalizationDomachowske et al. (2017)Multicenter RCTNRMultinationalOutpatient careand inpatient careMulticenter89Healthy infants< 12 monthsPCRSafety profileConsolati et al. (2024)Prospective cohortMay 2023 to February 2024ItalyOutpatient careand inpatient careSingle center556Healthy infants< 12 monthsNRRSV-bronchiolitisAlejandre et al. (2024)Prospective cohortSeptember 2010 and February 2024SpainInpatient careSingle center1531Healthy infants< 12 monthsPCRICU admissionRSV: respiratory syncytial virus. ICU-admission: intensive care unit admission. RSV-LRTIs: respiratory syncytial virus-related lower respiratory tract infections. PCR: polymerase chain reaction. RAT: rapid antigen test. NR: not reported*It was a substudy from MELODY study (Hammit et al., 2020) Study characteristics of the included studies bronchiolitis RSV-positive bronchiolitis rate July 2019 and October 2021 Outpatient care and inpatient care Outpatient care and inpatient care Outpatient care and inpatient care Outpatient care and inpatient care Outpatient care and inpatient care Outpatient care and inpatient care RSV: respiratory syncytial virus. ICU-admission: intensive care unit admission. RSV-LRTIs: respiratory syncytial virus-related lower respiratory tract infections. PCR: polymerase chain reaction. RAT: rapid antigen test. NR: not reported *It was a substudy from MELODY study (Hammit et al., 2020) Quality assessment and certainty of evidence ROB2 and NOS were used to assess the quality of included studies. The five included RCTs [26, 30, 31, 33, 34] were “low risk” of bias (Fig. 2). Eight observational studies were of good quality [10, 11, 22–24, 36–38] and eleven of moderate quality on the NOS scale [8, 9, 24, 25, 28, 29, 32, 35, 39–41]. The comparability domain was the frequent high-risk domain due to short-term follow-up and ascertainment of exposure. One study, Ruiz 2024 [27], was of low quality due to selection bias of the non-exposed cohort, and the follow-up was not long enough for outcomes to occur (Supplementary Table 2). Fig. 2ROB 2.0 graph for quality assessment of included studies ROB 2.0 graph for quality assessment of included studies GRADEPro was used to assess the certainty of evidence of the analyzed primary outcomes, both RSV-LRTIs and Hospitalization, through the three analyses: RCTs, observational cohorts, and Pooled IPD analysis. Both outcomes were of high certainty of evidence in RCTs and pooled IPD. However, there was low certainty in observational cohorts regarding the nature of observational studies, and the presence of high heterogeneity made both outcomes in the observational subgroup at low certainty (Supplementary Table 3). Outcomes Efficacy outcomes RSV-related Lower respiratory tract infections (RSV-LRTIs). RSV-related Lower respiratory tract infections (RSV-LRTIs). RSV-related Lower respiratory tract infections (RSV-LRTIs). RSV-LRTIs were reported in 14 studies: 5 RCTs and 9 observational cohort studies with 186,334 infants (119,953 in the nirsevimab group and 66,381 in the control group). The pooled analysis of the 14 studies showed that immunization with nirsevimab reduces the incidence of RSV-LRTIs by 63% (RR: 0.37; 95% CI [0.29; 0.47], p-value < 0.001, I2 = 91.77%) (Fig. 3). Sensitivity analysis by leaving one out was performed to show the source of high heterogeneity. After the individual exclusion of each study, the pooled RR was still significant between the remaining studies (Supplementary Fig. 1B). Fig. 3Forest plot meta-analysis for RSV-related Lower respiratory tract infections (RSV-LRTIs) Forest plot meta-analysis for RSV-related Lower respiratory tract infections (RSV-LRTIs) Subgroup analysis was performed based on the study design. In the observational subgroup, immunization with nirsevimab significantly reduced the RSV-LRTIs rates by 59% (RR: 0.41; 95% CI [0.31; 0.54]), (I2 = 94.49%, p-value < 0.001). These observational studies showed the cause of the high heterogeneity in the analysis. In the RCT subgroup, RSV-LRTI rates were reduced in the immunized with nirsevimab group by 74% (RR: 0.26; 95% CI [0.20; 0.35], I2 = 0%) (Supplementary Fig. 2). 2. Hospitalization due to RSV infection. 2. Hospitalization due to RSV infection. Hospitalization due to RSV infection. RSV-Hospitalization was reported in 16 studies: 5 RCTs and 11 observational cohort studies with 223,284 infants (150,969 in the nirsevimab group and 72,315 in the control group). The pooled analysis of 16 studies showed that immunization with nirsevimab reduces the incidence of hospitalization by 73% (RR: 0.27; 95% CI [0.20; 0.37], p-value < 0.001, I2 = 97.46%) (Fig. 4). Sensitivity analysis by leaving one out was performed to show the source of high heterogeneity. After the individual exclusion of each study, the pooled RR was still significant between the remaining studies (Supplementary Fig. 1B). Fig. 4Forest plot meta-analysis for hospitalization due to RSV infection Forest plot meta-analysis for hospitalization due to RSV infection Subgroup analysis was performed based on the study design: RCT or observational studies. In the observational subgroup, the immunization with nirsevimab significantly reduced the Hospitalization rates by 71% (RR: 0.29; 95% CI [0.20; 0.40], I2 = 98.25%), and these observational studies showed the cause of high heterogeneity in the analysis. In the RCT subgroup, Hospitalization rates were reduced in the immunized group with nirsevimab by 78% (RR: 0.22; 95% CI [0.15; 0.33], I2 = 0%) (Supplementary Fig. 3). 3. All-Cause Lower Respiratory Tract Infections (LRTIs). 3. All-Cause Lower Respiratory Tract Infections (LRTIs). All-Cause Lower Respiratory Tract Infections (LRTIs). The analysis of 6 included studies showed that all-cause LRTIs were significantly lower in the nirsevimab group compared to the control group (RR: 0.63; 95% CI [0.49; 0.82], p-value < 0.001, I2 = 95.02%) (Supplementary Fig. 4A). Sensitivity analysis by leaving one out was performed to show the source of high heterogeneity. After the individual exclusion of each study, the pooled RR was still significant between the remaining studies (Supplementary Fig. 4A). 4. All-Cause Hospitalizations. 4. All-Cause Hospitalizations. All-Cause Hospitalizations. The analysis of 8 included studies showed that all-cause hospitalizations were significantly lower in the nirsevimab group compared to the control group (RR: 0.82; 95% CI [0.70; 0.96], p-value = 0.01, I2 = 81.07%) (Supplementary Fig. 5A). Sensitivity analysis by leaving one out was performed to show the source of high heterogeneity. After the individual exclusion of each study, the pooled RR was still significant between the remaining studies except after exclusion of Perramon-Malavez 2025 [35], the pooled RR was statistically insignificant (Supplementary Fig. 5B). 5. ICU admission. 5. ICU admission. ICU admission. The immunization with nirsevimab was associated with a significant reduction in ICU admission rates (RR: 0.34; 95% CI [0.20; 0.58], p-value < 0.001, I2 = 87.08%) compared to the control group (Supplementary Fig. 6A). The Ares-Gomez 2024 and Gutierrez 2024 studies showed a skewed effect in the individual pooled estimate. The sensitivity analysis by leaving one out was performed to show the source of high heterogeneity. After the individual exclusion of each study, the pooled RR was still significant between the remaining studies (Supplementary Fig. 6B). 6. Bronchiolitis. 6. Bronchiolitis. Bronchiolitis. The immunization with nirsevimab reduced bronchiolitis by 52% (RR: 0.48; 95% CI [0.40; 0.57], p-value < 0.0001, I2 = 75.15%) (Supplementary Fig. 7A). The sensitivity analysis by leaving one out was performed to show the source of moderate heterogeneity. The results were still significant after excluding Domachowske 2017 [30], Drysdale 2023 [31], and Gutierrez 2024 [25]. However, it was insignificant after excluding Coma 2024 [28] and Buey 2024 [24] (Supplementary Fig. 7B). 7. Emergency Unit Visits. 7. Emergency Unit Visits. Emergency Unit Visits. The immunization with nirsevimab significantly reduced the rates of emergency visits (RR: 0.33; 95% CI [0.25; 0.43], p-value < 0.0001, I2 = 82.45%) compared to the control group (Supplementary Fig. 8A). The sensitivity analysis by leaving one out was performed to show the source of heterogeneity. After the individual exclusion of each study, the pooled RR was still significant between the remaining studies (Supplementary Fig. 8B). 8. Need for Mechanical Ventilation (MV). 8. Need for Mechanical Ventilation (MV). Need for Mechanical Ventilation (MV). The analysis showed that there was no difference between immunized and non-immunized groups in reducing rates of need for mechanical ventilation (RR: 0.89; 95% CI [0.73; 1.09], p-value = 0.27, I2 = 0.00%) (Supplementary Fig. 9A). The sensitivity analysis by leaving one out was performed to show the source of heterogeneity. After the individual exclusion of each study, the pooled RR was still significant between the remaining studies (Supplementary Fig. 9B). 9. All-cause Mortality. 9. All-cause Mortality. All-cause Mortality. The risk of all-cause mortality was similar between the two groups: immunized and not-immunized (RR: 0.27; 95% CI [0.09; 0.79], p-value = 0.02, I2 = 0.53%) (Supplementary Fig. 10A). The sensitivity analysis by leaving one out was performed to show the source of heterogeneity. After the individual exclusion of each study, the pooled RR was still significant between the remaining studies (Supplementary Fig. 10B). Safety outcomes there was no statistical significance between immunized infants and non-immunized infants in the risk of adverse events of special interest (RR: 1.09; 95% CI [0.37; 3.22], p-value = 0.88, I2 = 0.00%) (Supplementary Fig. 11A); the risk of Adverse events > grade 3 (RR: 0.81; 95% CI [0.64; 1.03], p-value = 0.08, I2 = 5.81%) (Supplementary Fig. 11B); the risk of serious adverse events (RR: 0.95; 95% CI [0.68; 1.32], p-value = 0.76, I2 = 58.10%) (Supplementary Fig. 12A); the risk of GIT adverse events (RR: 1.05; 95% CI [0.83; 1.33], p-value = 0.68, I2 = 43.20%) (Supplementary Fig. 11C); and the risk of infections or infestations (RR: 0.92; 95% CI [0.72; 1.17], p-value = 0.49, I2 = 87.78%) (Supplementary Fig. 13A). The sensitivity analysis by leaving one out was performed to show the source of moderate heterogeneity in the risk of serious adverse events. After excluding Drysdale 2023 [31], nirsevimab showed a significant risk to increase serious adverse events by 23% (RR: 0.77; 95% CI [0.62; 0.96], p-value = 0.020), but without any clinical significance. However, after excluding other studies, there were no statistical differences between the groups (p-value > 0.05) (Supplementary Fig. 12B). The sensitivity analysis by leaving one out was performed to show the source of heterogeneity in the risk of infections or infestations. After the individual exclusion of each study, the pooled RR was still insignificant (p > 0.05) between the remaining studies (Supplementary Fig. 13B). Publication bias The visual presentation of funnel plots of RSV-LRTIs revealed asymmetry in the funnel plot and possible publication bias. After the trim and fill methodology, no imputed studies were suggested and aligned with no publication bias (Supplementary Fig. 14). Also, the Egger’s test value was insignificant (p-value = 0.52) and revealed no publication bias (no small-study effects). However, the asymmetry in the funnel plot may be explained by the high heterogeneity in the primary analysis of this outcome. Most of the papers were distributed at the top of the plot, indicating small standard errors (SE) with large sample sizes and more precise estimates. For the hospitalization outcome, the funnel plot was asymmetry with possible publication bias. After the trim and fill methodology, still asymmetry of the funnel plot and aligned with the possibility of publication bias (Supplementary Fig. 15). The Egger’s test value was significant (p-value = 0.018) and revealed that there was a publication bias within the hospitalization rates due to RSV infections. High heterogeneity may be the cause of asymmetry in the funnel plots. Time-to-Event analysis RSV-LRTIs. RSV-LRTIs. RSV-LRTIs. Two RCTs reported the RSV-LRTIs risk in Kaplan-Meier (KM) curves across the 6 months. A total of 2,943 infants (1,963 in the nirsevimab group and 980 in the placebo group) were analyzed in the reconstructed curves. Our analysis showed that the single dose of nirsevimab reduced the risk of RSV-LRTIs by 75% (HR: 0.25; 95% CI [0.16; 0.37]) (Fig. 5B). The restricted mean survival time (RMST) was higher in the nirsevimab group compared to the placebo group (4.94 months; 4.80 months, respectively). The RMST difference between the two groups was (RMST diff: -0.15, 95% CI [-0.20; -0.09], p-value < 0.001) (Supplementary Table 4). Fig. 5Kaplan-Meier curves for the cumulative probability of RSV-related Lower respiratory tract infections (RSV-LRTIs) (A) and hospitalization due to RSV infection (B) Kaplan-Meier curves for the cumulative probability of RSV-related Lower respiratory tract infections (RSV-LRTIs) (A) and hospitalization due to RSV infection (B) 2. Hospitalization due to RSV infection. 2. Hospitalization due to RSV infection. Hospitalization due to RSV infection. Two RCTs reported the RSV-hospitalization risk in KM curves across the 6 months. A total of 9511 infants (5006 in the nirsevimab group and 4505 in the placebo group) were analyzed in the reconstructed curves. The risk of RSV-hospitalization was reduced after nirsevimab injection by 86% (HR: 0.14; 95% CI [0.08; 0.25]) (Fig. 5B). The RMST was higher in the nirsevimab group compared to the placebo group (4.98 months; 4.92 months, respectively). The RMST difference between the two groups was (RMST diff: -0.06, 95% CI [-0.08; -0.04], p-value < 0.001) (Supplementary Table 4). Discussion This systematic review investigated the safety and efficacy of nirsevimab in preventing serious RSV infections in neonates and infants. Our findings emerged from 26 studies conducted across 46 countries around the world, presenting 425,362 infants. We found that a single dose of nirsevimab demonstrated a significant reduction in the incidence of RSV-related hospitalizations and severe RSV lower respiratory tract infections (LRTIs) compared to placebo or standard care, supporting its potential prophylactic role for this vulnerable population. The safety profile of Nirsevimab was also favorable, with a few mild to moderate adverse events compared to those in control groups. Serious adverse events were rare and not significantly different between the nirsevimab and control groups, indicating that the treatment is suggested to be well-tolerated among neonates and infants. This safety assurance is critical for the acceptance and widespread use of nirsevimab in clinical practice, especially in pediatric populations. These results align with the growing body of evidence highlighting the potential of monoclonal antibodies in reducing the burden of RSV-related illnesses in young children and are consistent with the previous network meta-analysis conducted to evaluate the safety and efficacy of monoclonal antibodies for the prevention of respiratory syncytial virus in infants and children [45]. After a single dose of nirsevimab, LRTIs decreased by 63%. However, there was significant heterogeneity among the included studies in the analysis (I2 = 91.77%), which may be caused by including observational studies in the analysis with different clinical settings and different patient characteristics. These results aligned with the previous systematic review and meta-analyses, which reported a higher efficacy of nirsevimab against RS-LRTIs [12, 45, 46]. Also, this analysis concluded that hospitalization rates decreased by 73% after a single dose of nirsevimab, but there was significant heterogeneity in this analysis (I2 = 97.46%). These findings aligned with the meta-analyses, which showed that rates of hospital admissions related to RSV were lower after a single dose of nirsevimab [12, 45, 46]. Including observational studies with different settings was the main source of heterogeneity, as shown after subgrouping based on study design, where the heterogeneity was only found in the observational study subgroup rather than the RCTs one. Hospitalization rates from RSV are so important to infant morbidity and healthcare costs, so decreasing the rates has multiple benefits, including cost benefits for both patients and health systems. Regarding the prophylaxis for RSV infection, recent advances in monoclonal antibodies for the prevention of RSV infection are discussed. A recent meta-analysis was conducted by Rodriguez et al. (2025) to investigate the efficacy of palivizumab for the prevention of RSV infection. It stated that the incidence of hospitalization was significantly reduced after systemic palivizumab due to RSV infections across two years of follow-up (RR 0.33, 95% CI: [0.20 to 0.55]; I² = 0.00%), which proved the high efficacy of palivizumab in RSV prophylaxis [47]. The palivizumab currently remains the only licensed monoclonal antibody with low use due to its high cost [5]. Also, a network meta-analysis was conducted by Sun et al. (2023) to investigate the outcomes with motavizumab, nirsevimab, and palivizumab for RSV prevention. This study stated that RSV infections were significantly reduced after the three drugs, without any significant results of adverse effects [45]. These results align with our results, so it is recommended to include the nirsevimab in the protocols for the prevention of RSV infection. Regarding the cost-effectiveness of nirsevimab, a recent study conducted by Hutton et al. (2024) stated that nirsevimab might be a cost-effective way to reduce RSV infections [48]. However, the cost-effectiveness was influenced by the hospitalization costs and nirsevimab cost. So, the integration of nirsevimab for the immunization schedules may be beneficial. Notably, the accessibility and pricing of nirsevimab in low-resource settings is unclear and conflicting. So, emerging studies from the low-resource settings are needed. This analysis demonstrated that the safety profile of nirsevimab prophylaxis was acceptable and did not differ significantly between the nirsevimab and placebo groups. Our analysis showed that the risk of adverse events of special interest, serious adverse events, and GIT adverse events was similar between the two groups; these results state the safety of nirsevimab administration. These results were aligned with the individualized RCT results. The pooled analysis was conducted mostly by RCTs, without any observed heterogeneity. These results are consistent with the previous meta-analysis, which evaluated the safety of nirsevimab through a pooling of two RCTs [46]. One of the notable challenges in interpreting the results was the significant heterogeneity observed between the studies. This heterogeneity could be attributed to study design variations, population, and different clinical settings. Two studies, Buey 2024 [24] and Alejandre 2024 [22], included high-risk populations, such as pre-term infants or those with underlying health conditions, such as severe bronchiolitis, while others focused on the general neonatal population. Additionally, differences in follow-up durations and methods of RSV diagnosis may have contributed to the variability in outcomes. The overall estimates from the analyzed studies consistently aligned with the efficacy of nirsevimab, despite the high heterogeneity. Strengths and limitations One of the main strengths of our study is covering various clinical settings across multiple countries, including multicenter RCTs and regional real-world observational cohort studies that evaluate this point. We combined all available evidence on nirsevimab through a comprehensive search and screening process. To be more comprehensive, we addressed all available efficacy and safety outcomes across the included studies. Through this process, we provided a balanced assessment of the nirsevimab’s effects. Our analysis included multicenter, high-quality RCTs with large sample sizes. Especially, the time-to-event analysis was based only on these RCTs to obtain the time relation in both the RSV-related hospitalization and LRTIs. However, there are some limitations in this analysis. First, this is a relatively new topic, so the process of collecting the reports was so hard because of the limited number of published studies; the evidence in this study is based on a limited number of studies, despite our comprehensive search. This problem was identified by some systematic reviews on how to prevent RSV infections. To adjust that, we manually searched and screened for references and citations of included studies. Second, Specific characteristics of RSV infections lead to misdiagnosis on a large scale. And a collection of respiratory specimen samples could fail to spot the definite diagnosis at the stage of infection. So, false negative specimens are likely to occur. Collecting the samples from the upper airway tract instead of the lower tract may be a cause for false-negative results as well. Third, conducting some studies during the COVID pandemic may affect the results. In the MELODY study [26, 34], they collected half of the patients before and half of the patients after the declaration by the WHO that COVID-19 is a pandemic. Fourth, including both RCTs and observational studies in the same analysis raised a significant heterogeneity. And this high heterogeneity poses challenges in making definitive conclusions. The generalizability may be affected because the included studies had different RSV seasonality and effects of the COVID-19 pandemic. Fifth, the long-term effects of nirsevimab are still questionable because there is a lack of studies that have long-term follow-up periods. The included studies in our analysis had relatively short-term follow-up periods. Sixth, the inclusion of observational studies introduces bias because of confounding factors such as socioeconomic status, regional differences in healthcare access, and underlying health conditions. Also, some studies were conducted in Spain with the same clinical settings. That can affect the generalizability of our results. The subgroup analysis based on the study design stated that the results were consistent across the RCTs vs. observational studies subgroups and supported by the results of the time-to-event analysis of RCTs, which may give insight into the power of our results and the possibility of generalization. Seventh, the possibility of publication bias was stated across the hospitalization outcome which raises some concerns about the results. So, more large randomized controlled studies, besides the multicenter real-world studies, are needed to guide the healthcare professionals and guideline authorities about nirsevimab administration to infants for RSV prevention. Eighth, the time-to-event analysis had some limitations because we relied on the published KM curves not the original individual patient data, so the results should be interpreted carefully. Clinical and research implications The positive findings on the efficacy and safety of nirsevimab have important clinical implications. Given the limited options currently available for RSV prophylaxis, nirsevimab offers a promising alternative, especially for infants who are at higher risk of severe RSV infections. Considering the time consumed, neutralizing antibody levels after a month of using nirsevimab were reported to be 10-fold higher compared with palivizumab, which needs more monthly doses [44]. The potential to reduce hospitalizations and severe outcomes could significantly alleviate the healthcare burden associated with RSV, particularly during peak seasons. The global burden of RSV, particularly where limited health access is a barrier, such as in low-income countries, is overwhelming. The optimistic potentiality of the cost-effectiveness of utilizing nirsevimab, particularly among those with high risk, can counterbalance this barrier. Integration of nirsevimab into national immunization programs, according to CDC recommendations [44, 48], could decrease the RSV-related morbidity among infants. To enhance this evidence and robust it, we advise conducting pragmatic, large-scale multicenter RCTs with good and standardized protocols. Almost all included studies had short-term follow-up periods, and the long-term effects of nirsevimab after initial administration are still questionable. So, we encourage conducting large sample-sized RCTs and Observational studies to state the long-term effects. Conclusion Our analysis indicates that a single dose of nirsevimab is highly effective in reducing RSV-LRTIs, related hospitalizations, ICU admissions, and rates of bronchiolitis, with low safety concerns. Based on these results, we recommend incorporating this approach into pediatric care protocols, aiming to reduce the morbidity and healthcare costs associated with RSV. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2